@article{3183274,
    title = "Unmet Medical Needs in Metastatic Lung and Digestive Neuroendocrine
Neoplasms",
    author = "Capdevila, Jaume and Bodei, Lisa and Davies, Philippa and Gorbounova, and Vera and Jensen, Robert T. and Knigge, Ulrich P. and Krejs, Guenter J. and and Krenning, Eric and O'Connor, Juan Manuel and Peeters, Marc and and Rindi, Guido and Salazar, Ramon and Vullierme, Marie-Pierre and Pavel, and Marianne E. and Arnold, R. and Bartsch, D. and Baudin, E. and Bodei, L. and and Borbath, I and Capdevila, J. and Caplin, M. and Chen, J. and Costa, and F. and Couvelard, A. and Cwikla, J. B. and Davies, P. and de Herder, W. and W. and Falconi, M. and Falkerby, J. and Fazio, N. and Ferone, D. and and Frilling, A. and Garcia-Carbonero, R. and Glasberg, S. and Gorbunova, V and and Grossman, A. and Hoersch, D. and Jensen, R. T. and Kaltsas, G. and and Kloeppel, G. and Knigge, U. P. and Kos-Kudla, B. and Krejs, G. J. and and Krenning, E. and Kulke, M. and Lamberts, S. W. J. and van Dijkum, and Nieveen E. and O'Connor, J. M. and O'Toole, D. and Pape, U. F. and and Partelli, S. and Pavel, M. E. and Peeters, M. and Ramage, J. and Reed, and N. Simon Beatson and Rindi, G. and Rinke, A. and Ruszniewski, P. and and Sorbye, H. and Sundin, A. and Scoazec, J. Y. and Taal, B. G. and and Tiensuu, J. E. and Toumpanakis, C. and Valle, J. and Vullierme, M. P. and and Welin, S. and Wiedenmann, B. and ENETS 2016 Munich Advisory Board",
    journal = "ISRN Neuroendocrinology",
    year = "2019",
    volume = "108",
    number = "1",
    pages = "18-25",
    publisher = "Karger",
    issn = "2090-7982",
    doi = "10.1159/000493319",
    keywords = "Unmet medical needs; Neuroendocrine neoplasms; Metastasis; Biomarkers;
Imaging; Therapy",
    abstract = "Unmet medical needs are not infrequent in oncology, and these needs are
usually of higher magnitude in rare cancers. The field of neuroendocrine
neoplasms (NENs) has evolved rapidly during the last decade, and,
currently, a new WHO classification is being implemented and several
treatment options are available in the metastatic setting after the
results of prospective phase III clinical trials. However, several
questions are still unanswered, and decisions in our daily clinical
practice should be made with limited evidence. In the 2016 meeting of
the advisory board of the European Neuroendocrine Tumor Society (ENETS),
the main unmet medical needs in the metastatic NENs setting were deeply
discussed, and several proposals to try to solve them are presented in
this article, including biomarkers, imaging, and therapy."
}